REG - Diaceutics PLC - Issue of Share Options / PDMR Shareholdings

DiaceuticsAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250723:nRSW0266Sa&default-theme=true

RNS Number : 0266S  Diaceutics PLC  23 July 2025

Diaceutics PLC

("Diaceutics" or the "Company")

 

Issue of Share Options/PDMR Shareholdings

New York, Belfast and London, 23 July 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today announces the issue of
1,886,357 share options over ordinary shares of £0.002 each in the Company
("Share Options") to certain directors, members of the Company's senior
management team and other key staff, pursuant to the Company's Employee Share
Option Plan ("ESOP"). These awards are made in accordance with the Company's
long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as follows:

 

 Name                             Number of Share Options granted  Total no. of ordinary shares under option post grant  % of existing issued share capital  Performance Period
 Ryan Keeling, CEO                271,688                          1,339,298                                             1.58%                               3 years from 22 July 2025

 Nick Roberts, CFO                194,063                          619,335                                               0.73%                               3 years from 22 July 2025

 Jordan Clark, CDO                189,750                          329,497                                               0.39%                               3 years from 22 July 2025

 Jillian Beggs, CCO and PDMR      83,771                           188,851                                               0.22%                               3 years from 22 July 2025

 Sandra Blake, CPO and PDMR       86,250                           162,586                                               0.19%                               3 years from 22 July 2025

 Susanne Munksted, CPMO and PDMR  88,187                           323,423                                               0.38%                               3 years from 22 July 2025

 Other employees (64 persons)     972,648                          3,248,476                                             3.83%                               3 years from 22 July 2025

 

 

For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the
Share Options vest on a sliding scale up to 100%, where vesting is subject to
the satisfaction of certain performance criteria. The performance criteria are
based upon the growth during the Performance Period in Total Shareholder
Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and Adjusted
EBITDA Margin. For all other employees, the Share Options vest after three
years from the date of grant dependent upon continual employment and
satisfactory employee performance.

 

The Remuneration Committee will review the performance conditions at periodic
intervals to ensure they remain appropriate. As a result of any such review,
the Committee will retain discretion to amend the conditions where
appropriate, having regard to overall Company performance and wider
shareholder experience.

The exercise price of the Share Options is £0.002 per share which equates to
the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the
Company is 6,211,466 representing approximately 7.32% of its current issued
share capital of 84,812,636.

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         1.    Ryan Keeling                  CEO
                                                                  2.    Nick Roberts                  CFO
                                                                  3.    Jordan Clark                  CDO
                                                                  4.    Jillian Beggs                 CCO
                                                                  5.    Sandra Blake                  CPO
                                                                  6.    Susanne Munksted              CPMO
 2   Reason for notification
 a.  Position/Status                                              As above
 b.  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics plc
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.2p each

 b.  Identification Code                                          ISIN:  GB00BJQTGV64
 c.  Nature of the transaction                                    Grant of share options
 d.  Price(s) and volume(s)                                                          Price(s)                             Volume(s)
     1.                                                                                               Exercise price of 0.2p per share      2
                                                                                                                                            7
                                                                                                                                            1
                                                                                                                                            ,
                                                                                                                                            6
                                                                                                                                            8
                                                                                                                                            8
     2.                                                                                               Exercise price of 0.2p per share      1
                                                                                                                                            9
                                                                                                                                            4
                                                                                                                                            ,
                                                                                                                                            0
                                                                                                                                            6
                                                                                                                                            3
     3.                                                                                               Exercise price of 0.2p per share      1
                                                                                                                                            8
                                                                                                                                            9
                                                                                                                                            ,
                                                                                                                                            7
                                                                                                                                            5
                                                                                                                                            0
     4.                                                                                               Exercise price of 0.2p per share      8
                                                                                                                                            3
                                                                                                                                            ,
                                                                                                                                            7
                                                                                                                                            7
                                                                                                                                            1
     5.                                                                                               Exercise price of 0.2p per share      8
                                                                                                                                            6
                                                                                                                                            ,
                                                                                                                                            2
                                                                                                                                            5
                                                                                                                                            0
     6.                                                                                               Exercise price of 0.2p per share      8
                                                                                                                                            8
                                                                                                                                            ,
                                                                                                                                            1
                                                                                                                                            8
                                                                                                                                            7
 e.  Date of the transaction                                      22 July 2025
 f.  Place of the transaction                                     Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFZGZNKZMGKZG